

**evaluating
clinical
research**

Bengt D. Furberg and Curt D. Furberg

evaluating clinical research

All that glitters is not gold



 Springer

Bengt D. Furberg, MD, PhD
Associate Professor
S-434 46 Kungsbacka
Sweden
bengtfurberg@hotmail.com

Curt D. Furberg, MD, PhD
Professor
Division of Public Health Sciences
Wake Forest University School of Medicine
Medical Center Boulevard
Winston-Salem, NC 27157-1063
cfurberg@wfubmc.edu

ISBN-13: 978-0-387-72898-8

e-ISBN-13: 978-0-387-72899-5

Library of Congress Control Number: 2007930204

© 2007 Springer Science+Business Media, LLC

All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden.

The use in this publication of trade names, trademarks, service marks and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights.

Printed on acid-free paper.

9 8 7 6 5 4 3 2 1

springer.com

Contents

| | | |
|-------------------|--|-----|
| Chapter 1 | What is the purpose of this book? | 1 |
| Chapter 2 | Why is benefit-to-harm balance essential to treatment decisions? | 5 |
| Chapter 3 | What are the strengths of randomized controlled clinical trials? | 11 |
| Chapter 4 | What are the weaknesses of randomized controlled clinical trials? | 17 |
| Chapter 5 | Do meta-analyses provide the ultimate truth? | 23 |
| Chapter 6 | What are the strengths of observational studies? | 29 |
| Chapter 7 | What are the weaknesses of observational studies? | 35 |
| Chapter 8 | Were the scientific questions stated in advance? | 39 |
| Chapter 9 | Were the treatment groups comparable initially? | 45 |
| Chapter 10 | Why is blinding/masking so important? | 49 |
| Chapter 11 | How is symptomatic improvement measured? | 53 |
| Chapter 12 | Is it really possible to assess quality of life? | 57 |
| Chapter 13 | What is the value of biologic markers in drug evaluation? | 61 |
| Chapter 14 | How are adverse drug reactions measured? | 67 |
| Chapter 15 | How representative are study subjects in clinical trials? | 73 |
| Chapter 16 | What happened to the study subjects who disappeared from the analysis? | 77 |
| Chapter 17 | How reliable are active-control trials? | 83 |
| Chapter 18 | How informative are composite outcomes? | 89 |
| Chapter 19 | Do changes in biologic markers predict clinical benefit? | 95 |
| Chapter 20 | How trustworthy are the authors? | 99 |
| Chapter 21 | Does publication in a reputable scientific journal guarantee quality? | 103 |
| Chapter 22 | Is it necessary to be a biostatistician to interpret scientific data? | 107 |
| Chapter 23 | Are all drugs of a class interchangeable? | 115 |
| Chapter 24 | How much confidence can be placed on economic analysis? | 121 |
| Chapter 25 | How should I handle the massive flow of information? | 125 |
| Chapter 26 | How well is research translated into clinical care? | 131 |
| Appendix A | Glossary | 137 |
| Appendix B | Explanations for checklist questions | 143 |
| References | | 149 |
| Index | | 159 |
| About the Authors | | 163 |